DHFR and primary cutaneous T-cell non-Hodgkin lymphoma: A number of therapies are currently used for the treatment of CTCL and given that single agent therapy is rarely beneficial, we tested Bexarotene (highly selective retinoid x receptor agonist), Methotrexate (inhibitor of dihydrofolate reductase), or ATRA (All Trans Retinoic Acid, a retinoic acid receptor agonist) [1], [41]–[43] for cooperative cell killing with 966.